New CAR-T therapy aims to outperform standard for Tough-to-Treat lymphoma
NCT ID NCT07479797
Summary
This study aims to see if a new CAR-T cell therapy called KITE-753 works better than the currently approved therapy, axicabtagene ciloleucel, for adults with large B-cell lymphoma that has come back or didn't respond to their first treatment. It will enroll about 550 participants and directly compare how well the two treatments control the cancer and improve quality of life. The main goal is to see if more people achieve a complete remission with KITE-753.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.